Tyrosine kinase inhibitorInvestigationalInvestigational
Apatinib
How it works
Apatinib is a tyrosine kinase inhibitor that works by blocking the VEGFR-2 receptor on cancer cells, which can slow or stop the growth of the disease.
Cancer types
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Combination Therapy for Advanced Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Combination Therapy Shows Promise for Advanced Mucosal Melanoma | Melanoma | phase-2 | The disease control rate reached 100% (SD = 13). | Source → |
| Combining Apatinib with EGFR-TKI May Help Lung Cancer Patients | Lung Cancer | phase-2 | The progression-free survival (PFS) of the Apatinib group was significantly longer than that of the chemotherapy group (10.5 months vs. 5.7 months). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.